Revolution Medicines Inc (RVMD) — the peer cohort

As of 2026-09-23 — scores re-bake nightly. Cohort = shared Closelook index membership first, then sector. Diary readings, not advice.

Revolution Medicines Inc ranks 7 of 7 in its cohort on the Closelook composite (29/100) — the cohort is led by BB Biotech AG at 74/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
RVMD Revolution Medicines Inc 29 80 1 info 15%
BION.SW BB Biotech AG 74 69 96 80 info 9.6%
ARGX.BR Argen-X 64 74 75 28 ok 9.6%
ARGX argenx NV ADR 64 74 74 27 ok 11.8%
ONC BeiGene, Ltd. 64 81 64 32 ok 5.2%
CAI Caris Life Sciences, Inc. Common Stock 60 82 61 31 ok 6%
REGN Regeneron Pharmaceuticals Inc 60 68 71 50 bull 6.7%

Scores are relative readings across the Closelook coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-09-23

Quick answers

Who are Revolution Medicines Inc's peers in the Closelook universe?

The cohort is drawn from shared Closelook index membership first, then sector: BB Biotech AG (BION.SW), Argen-X (ARGX.BR), argenx NV ADR (ARGX), BeiGene, Ltd. (ONC), Caris Life Sciences, Inc. Common Stock (CAI), Regeneron Pharmaceuticals Inc (REGN).

How does RVMD score against its peers?

Revolution Medicines Inc's composite reads 29/100, ranking 7 of 7 in its cohort as of 2026-09-23; the cohort's highest composite is BB Biotech AG at 74/100. Closelook scores are research diary readings, not ratings or advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.